The company said that since this manufacturing facility is already under USFDA import alert and presently not doing any US business, this will have no impact on company's current on-going business activities. The USFDA inspection of its Piparia (Silvassa) formulations manufacturing unit in August resulted in three observations.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35zunn1
via IFTTT
0 comments:
Post a Comment